(E,3S)-3-hydroxy-7-tritylsulfanyl-hept-4-enoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (E,3S)-3-hydroxy-7-tritylsulfanyl-hept-4-enoic acid
• 英文别名: 3-hydroxy-7-tritylsulfanylhept-4-enoic acid
• 化学式: C₂₆H₂₆O₃S
• 分子量: 418.5
• InChiKey: BGUJCVRJDCZLQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  82.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Depsipeptides and Their Therapeutic Use
  申请人：Shuttleworth Stephen Joseph

  公开号：US20110112090A1

  公开（公告）日：2011-05-12

  A Compound of structure (IX) or (X) or a pharmaceutically acceptable salt thereof, wherein: X is —C(═O)N(R 10 )— or —CH(OPr 3 )—; R 7 , R 9 and R 10 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid; Pr 1 and Pr 2 are the same or different and represent hydrogen or a thiol protecting group; Pr 3 is hydrogen or an alcohol protecting group; R 1 , R 2 , R 5 and R 6 are the same or different and represent hydrogen or an amino acid side chain moiety from either a natural or an unnatural amino acid, or R 1 and R 2 and/or R 5 and R 6 , taken together with the carbon atom to which they are attached, form a spirocyclic moiety, with the proviso that: each of R 1 and R 2 is not hydrogen, or each of R 5 and R 6 is not hydrogen.

  一种结构化合物（IX）或（X）或其药学上可接受的盐，其中：X为—C(═O)N(R10)—或—CH(OPr3)—；R7、R9和R10相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团；Pr1和Pr2相同或不同，代表氢或巯基保护基团；Pr3为氢或醇保护基团；R1、R2、R5和R6相同或不同，代表氢或来自天然或非天然氨基酸的氨基酸侧链基团，或R1和R2和/或R5和R6，与它们连接的碳原子一起形成螺环基团，条件是：R1和R2中的每一个都不是氢，或R5和R6中的每一个都不是氢。
• [EN] NOVEL HDAC INHIBITORS AND METHODS OF TREATMENT USING THE SAME<br/>[FR] NOUVEAUX INHIBITEURS DE HDAC ET MÉTHODES D'UTILISATION DE CES DERNIERS
  申请人：UWM RES FOUND INC

  公开号：WO2017039726A1

  公开（公告）日：2017-03-09

  Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder.

  本文披露了新型HDAC抑制剂。这些HDAC抑制剂可用于治疗癌症的方法。这些HDAC抑制剂可用于治疗神经系统疾病的方法。
• [EN] AN IMPROVED PROCESS FOR THE PREPARATION OF (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ETHYLIDENE-4,21-BIS(1-METHYLETHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TETRAAZABICYCLO[8.7.6]TRICOS-16-ENE-3, 6, 9, 19, 22-PENTONE<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR LA PRÉPARATION DE (1S, 4S, 7Z, 10S, 16E, 21R)- 7-ÉTHYLIDÈNE-4,21-BIS(1-MÉTHYLÉTHYL)-2-OXA-12,13-DITHIA-5, 8, 20, 23- TÉTRAAZABICYCLO[8.7.6]TRICOS-16-ÈNE-3, 6, 9, 19, 22-PENTONE
  申请人：MSN LABORATORIES PRIVATE LTD

  公开号：WO2017068596A1

  公开（公告）日：2017-04-27

  The present invention is relates to an improved process for the preparation (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabi-cyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone of formula I.

  本发明涉及一种改进的制备过程，用于制备式I的(1S,4S,7Z,10S,16E,21R)-7-乙烯基-4,21-双(1-甲基乙基)-2-氧-12,13-二硫-5,8,20,23-四氮杂环[8.7.6]三十一烯-16-烯-3,6,9,19,22-五酮。
• [EN] METHOD FOR PREPARING LARGAZOLE ANALOGS AND USES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PARTICULES CREUSES ET LEURS UTILISATIONS
  申请人：UNIV COLORADO STATE RES FOUND

  公开号：WO2016144665A1

  公开（公告）日：2016-09-15

  Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

  本文描述了类似largazole的类似物。此外，还描述了使用largazole和largazole类似物治疗癌症和血液疾病的方法，以及包含它们的药物组合物。同样描述了制备largazole类似物的方法。
• Process for the preparation of (1S, 4S, 7Z, 10S, 16E, 21R)-7-ethyldene-4,21-bis(1-methyl-ethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3, 6, 9, 19, 22-pentone
  申请人：Rajan Srinivasan Thirumalai

  公开号：US10562931B2

  公开（公告）日：2020-02-18

  The present invention is relates to an improved process for the preparation (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabi-cyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone of formula I.

  本发明涉及一种制备式 I 的(1S,4S,7Z,10S,16E,21R)-7-亚乙基-4,21-双(1-甲基乙基)-2-氧杂-12,13-二硫杂-5,8,20,23-四氮杂双环[8.7.6]三os-16-烯-3,6,9,19,22-戊酮的改进工艺。